Mounjaro (Tirzepatide): The Dual-Action GLP-1 That Changed the Game

Mounjaro arrived in 2022 and quickly became the most-prescribed weight-loss medication in clinics that could get hold of it. It is tirzepatide — and unlike semaglutide (Ozempic, Wegovy), it activates two receptors instead of one.

How tirzepatide works

Most GLP-1 drugs hit only the GLP-1 receptor. Tirzepatide is a "twincretin" — it activates both the GLP-1 and the GIP receptor. GIP (glucose-dependent insulinotropic polypeptide) is the other major gut hormone that regulates insulin and appetite.

In practice this matters because:

• Activating both receptors produces stronger appetite suppression than either alone.
• The combination appears to preserve more lean mass at equivalent weight loss in some sub-analyses (data is still emerging).
• The metabolic effects on insulin sensitivity are broader.

Dosing

Mounjaro titrates in 2.5 mg steps:

• Weeks 1–4: 2.5 mg/week (starter — not therapeutic)
• Weeks 5–8: 5 mg/week
• Weeks 9–12: 7.5 mg/week (optional)
• Then: 10 mg, 12.5 mg, or 15 mg as tolerated

Most weight-loss patients land at 10 mg or 12.5 mg. The jump from 10 → 15 mg adds modest additional weight loss with a noticeable bump in GI side effects.

What to expect

The published trials are striking. SURMOUNT-1 showed average weight loss at 15 mg of about 21% over 72 weeks — meaningfully more than semaglutide's ~15%. About a third of patients on the highest dose lost more than 25% of their body weight.

But the muscle-loss problem does not disappear with a stronger drug — if anything, faster fat loss puts more pressure on lean mass. The same protein floor and resistance-training rules apply, and the SURMOUNT body-composition sub-studies confirm that lean mass loss is non-trivial.

Side effects

Tirzepatide's side-effect profile is similar to semaglutide:

• Nausea (most common, especially during titration)
• Diarrhea or constipation
• Decreased appetite (the goal, but it can become extreme)
• Fatigue, especially in the first month at each new dose
• Sulfur burps (more reported with tirzepatide than semaglutide, anecdotally)
• Injection site reactions (less common than older GLP-1s)

Serious risks (rare): pancreatitis, gallbladder disease, kidney issues, thyroid concerns (boxed warning).

Mounjaro vs Zepbound

The same molecule, tirzepatide, is sold under two brand names:

• Mounjaro — approved for type 2 diabetes
• Zepbound — approved for chronic weight management

Insurance coverage usually follows the indication. The pens are functionally identical; only the box and the FDA label differ.

The compound supply story

Throughout 2023–2024, both semaglutide and tirzepatide were on the FDA shortage list, which legally allowed compounding pharmacies to produce them. As supplies have stabilized, the FDA has restricted compounded versions. We have a separate guide on compounded GLP-1 — the short version: brand-name product is the only fully-validated option, and counterfeit pens are now common in the gray market.

Bottom line

Tirzepatide is, on average, the most effective GLP-1 currently on the market. It still requires the same things every other GLP-1 requires: a protein floor, resistance training, and a maintenance plan. Stronger appetite suppression is not a substitute for the work that protects your shape. It is an even bigger reason to do it.